Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) saw a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 993,300 shares, a growth of 12.7% from the April 30th total of 881,600 shares. Based on an average daily volume of 86,600 shares, the days-to-cover ratio is currently 11.5 days. Approximately 6.6% of the shares of the company are sold short.
Separately, Zacks Investment Research lowered shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a research report on Thursday, July 4th.
NASDAQ:KNSA traded down $0.75 during mid-day trading on Friday, hitting $13.77. 59,060 shares of the company’s stock were exchanged, compared to its average volume of 146,248. Kiniksa Pharmaceuticals has a fifty-two week low of $13.04 and a fifty-two week high of $32.88. The stock’s 50 day moving average is $14.43. The company has a market cap of $753.23 million, a price-to-earnings ratio of -3.95 and a beta of -1.54.
Several large investors have recently added to or reduced their stakes in KNSA. BNP Paribas Arbitrage SA increased its stake in shares of Kiniksa Pharmaceuticals by 1,131.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,685 shares of the company’s stock valued at $48,000 after acquiring an additional 2,467 shares in the last quarter. Barclays PLC increased its stake in shares of Kiniksa Pharmaceuticals by 25.7% in the 4th quarter. Barclays PLC now owns 3,054 shares of the company’s stock valued at $86,000 after acquiring an additional 624 shares in the last quarter. New York State Common Retirement Fund bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at $107,000. Rhumbline Advisers bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at $223,000. Finally, D. E. Shaw & Co. Inc. bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at $268,000. Institutional investors own 29.76% of the company’s stock.
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Read More: Marijuana Stocks
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.